RESUMO
INTRODUCTION: The objective of this study was to investigate the effect of mivacurium in the application of fast-track anesthesia for transthoracic device closure of ventricular septal defects (VSDs) in children. METHODS: The data of 108 children who underwent transthoracic device closure of VSDs from December 2018 to June 2020 were recorded and analyzed. All children were divided into group M (mivacurium group, n=55) and group C (cisatracurium group, n=53) according to the different muscle relaxant drug used. RESULTS: No statistically significant differences in general preoperative data, intraoperative hemodynamic changes, or the incidence of adverse reactions were noted between the two groups (P>0.05). However, the intubation condition rating of children in group M was better than that in group C. The onset time, duration of clinical action and recovery index of the muscle relaxant, postoperative mechanical ventilation duration, and length of intensive care unit stay in group M were significantly lower than those in group C (P<0.05). CONCLUSION: It is safe and feasible to use mivacurium as a muscle relaxant in children undergoing fast-track cardiac anesthesia during transthoracic device closure of VSDs.
Assuntos
Anestesia em Procedimentos Cardíacos , Anestesia , Comunicação Interventricular , Dispositivo para Oclusão Septal , Criança , Comunicação Interventricular/cirurgia , Humanos , Mivacúrio , Respiração Artificial , Estudos Retrospectivos , Resultado do TratamentoRESUMO
BACKGROUND: We aimed to investigate the effects of metoclopramide and ondansetrone on mivacurium neuromuscular blockade. METHODS: Seventy five, ASA I-II patients, aged 18-65 and scheduled for elective surgery requiring tracheal intubation were included in the study. The patients received metoclopramide 10 mg, ondansetrone 4 mg or normal saline 5 mL; group M, group O, group NS (n=25), respectively. Before anesthesia study drugs were administered in a volume of 5 mL. The level of plasma cholinesterase were obtained before and 5 minutes after the administration of study drugs and 5 minutes after the administration of mivacurium. Onset time, T25, T75, T25-75, T90 levels were compared with each other and differences between each patients were investigated. After recording T90, the study was terminated and surgery was started. RESULTS: Onset time was significantly shorter in group M, than the other two groups. Onset time in group O was significantly shorter than in group NS. In Group M T25, T75, T90 and recovery indices were significantly greater than in Group NS (p<0.001). In Group O T25, T75 were greater than Group NS (p<0.01 and p<0.05, respectively). In Group M T75, T90 and emergence indices were significantly higher than Group O (p<0.001, p<0.01, p<0.001, respectively). In Groups M and O, plasma cholinesterase levels decreased significantly (p<0.001) after administration of study drugs and mivacurium. Plasma cholinesterase also was reduced in Group NS 5 minutes after the administration of mivacurium (p<0.001). CONCLUSION: Ondansetrone is believed to be more reliable agent than metoclopramide when used with mivacurium.
Assuntos
Isoquinolinas/farmacologia , Metoclopramida/uso terapêutico , Bloqueio Neuromuscular , Fármacos Neuromusculares não Despolarizantes/farmacologia , Ondansetron/uso terapêutico , Adulto , Colinesterases/sangue , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mivacúrio , Estudos ProspectivosRESUMO
OBJECTIVES: Succinylcholine (SCH) may first be used and continue with mivacurium (MIV). MIV has been suggested as a pretreatment. Conflicting results arises from studies on SCH-MIV interaction. The following trial revisits this interaction. PATIENTS AND METHODS: The patients were intubated after randomized administration of 100 microg x Kg(-1) of mivacurium (group 1) or 1 mg x Kg(-1) of succinylcholine and, after 50% recovery, 100 microg x Kg(-1) of mivacurium (group 2). A third group received the same regimen as group 2, preceded by pretreatment with 10 microg x Kg(-1) of mivacurium. Maximum effect (MAX), onset time, the 10%-25% recovery index, and duration of effect of mivacurium were determined by electromyography. In groups 2 and 3, the corrected MAX was defined as the difference between the actual MAX effect and the residual block after administration of succinylcholine, and speed of action was defined as the ratio between MAX or corrected MAX and onset time. Data were subjected to analysis of variance and Student-Newman-Keuls and t tests for bivariate comparisons. A value of P less than 0.05 was considered significant. RESULTS: Groups 2 and 3 had significantly greater MAX effects (97% and 98%, respectively) in comparison with group 1 (93%), shorter onset times (135 and 158 seconds in groups 2 and 3 vs 279 seconds in group 1), and greater speed of action without changes in duration of effect. MAX was halved when corrected (to 47% and 49% in groups 2 and 3, respectively), and speed of action was significantly reduced (from 1.34 and 1.62 seconds/% in groups 2 and 3 respectively, to 2.69 and 3.36 seconds/%). Mivacurium pretreatment did not produce relevant clinical changes. CONCLUSIONS: When mivacurium is used before the effects of succinylcholine disappear, a residual effect is not usually taken into consideration. This study corrected MAX and calculated speed of action, demonstrating a reduction in net block and speed of action, consistent with an antagonistic action when the 2 blockers are administered sequentially.
Assuntos
Isoquinolinas/farmacologia , Fármacos Neuromusculares Despolarizantes/farmacologia , Fármacos Neuromusculares não Despolarizantes/farmacologia , Succinilcolina/antagonistas & inibidores , Adulto , Idoso , Esquema de Medicação , Procedimentos Cirúrgicos Eletivos , Eletromiografia , Feminino , Humanos , Isoquinolinas/administração & dosagem , Isoquinolinas/farmacocinética , Masculino , Pessoa de Meia-Idade , Mivacúrio , Fármacos Neuromusculares Despolarizantes/administração & dosagem , Fármacos Neuromusculares Despolarizantes/farmacocinética , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Succinilcolina/administração & dosagem , Succinilcolina/farmacocinéticaRESUMO
The aim of this study is to present the pharmacodynamics of the priming principle using rapacuronium and a comparison with rocuronium and mivacurium. After induction, 120 patients were randomly allocated to six similar groups. Groups 1 and 2 received rapacuronium 1000 micrograms.Kg-1 as a bolus or primed with 100 micrograms.Kg-1. To groups 3 and 4, rocuronium 400 micrograms.Kg-1 were given as a bolus or primed with 60 micrograms.Kg-1, finally mivacurium 100 micrograms.Kg-1 was used for groups 5 and 6 by bolus or primed with 10 micrograms.Kg-1. Neuromuscular function was monitored by electromyography and it was demonstrated that time to 80% blockade, is significantly shorter after priming: 137 (bolus) vs 101 seconds (priming) for rapacuronium, 160 vs 90 for rocuronium and 196 vs 118 for mivacurium. Onset time was also statistically accelerated by priming: 229 seconds vs 183, 289 vs 203 and 298 vs 252 respectively. No significant change was noticed in maximal blockade and clinical duration due to priming. During early onset, only the mivacurium patients showed a statistical difference in train of four fade between bolus and priming. In conclusion, priming hasten early and maximal effect produced by rapacuronium, rocuronium and mivacurium without any change in maximal blockade and clinical duration. Pre-synaptic effect does not explain consistently the mode of action of priming.
Assuntos
Androstanóis/administração & dosagem , Isoquinolinas/administração & dosagem , Bloqueio Neuromuscular/métodos , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Brometo de Vecurônio/análogos & derivados , Brometo de Vecurônio/administração & dosagem , Adulto , Idoso , Androstanóis/farmacocinética , Procedimentos Cirúrgicos Eletivos/métodos , Eletromiografia , Feminino , Humanos , Isoquinolinas/farmacocinética , Masculino , Pessoa de Meia-Idade , Mivacúrio , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Rocurônio , Fatores de Tempo , Brometo de Vecurônio/farmacocinéticaRESUMO
INTRODUCTION: Myasthenia gravis is an autoimmune disease characterized by the presence of circulating IgG antibodies, which interact with acetylcholine receptors and interfere with neuromuscular transmission. OBJECTIVES: To compare neuromuscular function when mivacurium is used in patients with myasthenia gravis and patients with no impairment of transmission at the neuromuscular synapse. MATERIAL AND METHOD: Prospective study of 40 patients in two groups. Group I (n = 20) consisted of patients with no impairment of neuromuscular transmission who underwent sternotomy or mediastinoscopy and who received 2 ED95 of mivacurium. Group II (n = 20) were patients with myasthenia gravis who underwent transsternal thymectomy and received 0.5 ED95 of mivacurium (50 micrograms/Kg). The neuromuscular function of all patients was monitored by accelerometry of the thumb adductor. RESULTS: All demographic variables except sex were similar in the two groups. Time to maximal block, duration of block and the recovery at T1 25-75 were significantly greater in group II (250 +/- 10 s, 29.1 +/- 2.4 min and 8.1 +/- 1.5 min, respectively) than in group I (188 +/- 13 s, 21.2 +/- 0.4 min and 7.1 +/- 0.2 min in group I). Maintenance doses were given more often in group I. At the end of surgery and before recovery from mivacurium, the mean twitch height in group II was 89.3 +/- 0.5%, such that tracheal tubes were removed from 95% of the patients without complications. The mean time until extubation in group II was 17.8 +/- 1.3 min and was related to the extension of the blocks. The differences were statistically significant (p < 0.05). CONCLUSIONS: The anesthetic effect of mivacurium was twice as great in myasthenic patients, in whom it behaved like an intermediate-level non-depolarizing muscle relaxant. Mivacurium can reduce prolonged mechanical ventilation in patients who are myasthenic or pharmacologically immunosuppressed and at risk of sepsis arising in the respiratory tract.
Assuntos
Período Intraoperatório , Isoquinolinas/uso terapêutico , Miastenia Gravis/complicações , Fármacos Neuromusculares não Despolarizantes/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Timectomia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mivacúrio , Estudos Prospectivos , Esterno , Timectomia/métodosRESUMO
The interaction between Mivacurium and several muscle relaxants results in a slow recovery. We have previously described that small doses of d-tubocurarine prolong the duration of two successful administrations of Mivacurium. The present investigation was designed to uncover if such an effect could be observed after other neuro-muscular blocking drugs were administered, and if so, its consistency during the different methods of their use. Patients (n = 224) were anesthetized with Enflurane and randomly assigned to two control groups which received 100 micrograms/Kg-1 Mivacurium as a bolus or primed. Other groups received: Rocuronium (60 micrograms/Kg-1), Vecuronium (10 micrograms/Kg-1), Atracurium (60 micrograms/Kg-1), d-tubocurarine (50 micrograms/Kg-1) or Pancuronium (8 micrograms/Kg-1) before, after or as a mixture with 90 micrograms/Kg-1 of Mivacurium. The clinical effect was monitored by electromyography and the results show that all these agents prolong the duration of Mivacurium, the last three in a statistically significant fashion independently of the mode of administration. Current hypothesis are reviewed, but no definitive clues are obtained to explain the present results. Our conclusions must be considered as further research on the interaction between non-depolarizing muscle relaxants and a base for new theories on interactions.
Assuntos
Isoquinolinas/farmacologia , Fármacos Neuromusculares não Despolarizantes/farmacologia , Análise de Variância , Estudos de Casos e Controles , Interações Medicamentosas , Eletromiografia , Humanos , Isoquinolinas/uso terapêutico , Mivacúrio , Fármacos Neuromusculares não Despolarizantes/uso terapêutico , Fatores de TempoRESUMO
STUDY OBJECTIVE: To determine the potentiation of the neuromuscular blockade induced by a titrated infusion of mivacurium in the presence of isoflurane versus a nitrous oxide (N2O)-opioid anesthesia. DESIGN: An open-label, controlled study. SETTING: The inpatient anesthesia service of two university medical centers. PATIENTS: Thirty adults divided into two groups. INTERVENTION: An intravenous infusion of mivacurium during anesthesia with N2O-opioid or N2O-isoflurane. MEASUREMENTS AND MAIN RESULTS: A neuromuscular blockade was monitored by recording the electromyographic activity of the adductor pollicis muscle resulting from supramaximal stimulation at the ulnar nerve at 2 Hz for 2 seconds at 10-second intervals. The mivacurium infusion rate was significantly less in the presence of isoflurane [4.0 +/- 0.8 micrograms/kg/min (mean +/- SEM)] than during N2O-opioid anesthesia (6.4 +/- 0.6 micrograms/kg/min). The recovery rates did not differ between anesthetic groups. After the termination of the infusion, spontaneous recovery to T4/T1 of at least 0.75 occurred in an average of 17.9 +/- 1.5 minutes, with a mean recovery index (T25-75) of 6.0 +/- 0.7 minutes. CONCLUSION: Isoflurane anesthesia reduces the infusion rate of mivacurium required to produce about 95% depression of neuromuscular function.
Assuntos
Anestesia Geral , Fentanila , Isoflurano , Isoquinolinas , Junção Neuromuscular/efeitos dos fármacos , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Óxido Nitroso , Adulto , Idoso , Sinergismo Farmacológico , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , MivacúrioRESUMO
The neuromuscular and cardiovascular effects of mivacurium were studied in 90 adult patients during nitrous oxide-oxygen-isoflurane (n = 45, ISO group) and nitrous oxide-oxygen-narcotic (n = 45, BAL group) anesthesia. Neuromuscular blockade was measured using electromyographic activity of the adductor pollicis muscle after supramaximal stimulation of the ulnar nerve at 2 Hz for 2 seconds at 10-second intervals. To estimate dose-response relations, three subgroups of nine patients in the ISO group received mivacurium doses of 0.025, 0.03, and 0.04 mg/kg, respectively. Similarly, three subgroups of nine patients in the BAL group received mivacurium doses of 0.03, 0.04, and 0.05 mg/kg, respectively. The ED50 and ED95 of mivacurium in each group were estimated from linear regression plots of log dose vs probit of maximum percentage depression of neuromuscular function. The estimated ED50 values for the ISO and BAL groups were 0.029 and 0.041 mg/kg, respectively. The estimated ED95 values for the ISO and BAL groups were 0.045 and 0.058 mg/kg, respectively. Recovery indexes were measured in 26 patients who received ED95 or greater doses of mivacurium in either the ISO or BAL groups. The recovery index was shorter in the BAL group (5.5 +/- 1.6 minutes [n = 10]), than in the ISO group (7.4 +/- 3.0 minutes [n = 16]). The addition of isoflurane (0.5-0.75% end-tidal concentration) to nitrous oxide-narcotic anesthesia augments the degree of neuromuscular blockade from a given dose of mivacurium and also prolongs the recovery index.